- Home
- NPCT vs AGEN Comparison
NPCT vs AGEN Comparison
Compare NPCT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- AGEN
- Stock Information
- Founded
- NPCT 2020
- AGEN 1994
- Country
- NPCT United States
- AGEN United States
- Employees
- NPCT N/A
- AGEN N/A
- Industry
- NPCT Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NPCT Finance
- AGEN Health Care
- Exchange
- NPCT Nasdaq
- AGEN Nasdaq
- Market Cap
- NPCT 340.7M
- AGEN 97.7M
- IPO Year
- NPCT N/A
- AGEN 2000
- Fundamental
- Price
- NPCT $11.34
- AGEN $4.49
- Analyst Decision
- NPCT
- AGEN Buy
- Analyst Count
- NPCT 0
- AGEN 3
- Target Price
- NPCT N/A
- AGEN $10.00
- AVG Volume (30 Days)
- NPCT 107.1K
- AGEN 339.2K
- Earning Date
- NPCT 01-01-0001
- AGEN 11-05-2024
- Dividend Yield
- NPCT 9.82%
- AGEN N/A
- EPS Growth
- NPCT N/A
- AGEN N/A
- EPS
- NPCT N/A
- AGEN N/A
- Revenue
- NPCT N/A
- AGEN $159,630,000.00
- Revenue This Year
- NPCT N/A
- AGEN N/A
- Revenue Next Year
- NPCT N/A
- AGEN $0.04
- P/E Ratio
- NPCT N/A
- AGEN N/A
- Revenue Growth
- NPCT N/A
- AGEN 60.67
- 52 Week Low
- NPCT $8.58
- AGEN $4.18
- 52 Week High
- NPCT $10.63
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- NPCT 31.22
- AGEN 40.14
- Support Level
- NPCT $11.46
- AGEN $4.50
- Resistance Level
- NPCT $11.55
- AGEN $4.78
- Average True Range (ATR)
- NPCT 0.15
- AGEN 0.28
- MACD
- NPCT -0.05
- AGEN 0.02
- Stochastic Oscillator
- NPCT 9.68
- AGEN 42.47
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).